Practice Parameter: Management of Dementia (An Evidence-Based Review)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The National Drugs List
^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ. -
WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al. -
Inline-Supplementary-Material-1.Pdf
Appendix 1: STOPP/START criteria version 2 applied to the TRUST dataset Physiological system Criteria Criteria included Number (%) (The relevant () criteria for each participant were applied to the dataset and recorded in of Microsoft Office Excel ® (2013)) criteria included out of total criteria STOPP criteria Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. X 1/3 (33.3) A2. Any drug prescribed beyond the recommended duration, where treatment duration is X well defined. A3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent). Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence X 7/13 (53.8) of benefit). B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of profound hypotension, asystole). B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias X (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem). B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more appropriate). B8. Thiazide diuretic with current significant hypokalaemia (i.e. -
Wo 2007/128674 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 15 November 2007 (15.11.2007) PCT WO 2007/128674 A2 (51) International Patent Classification: Houtenlaan 36, NL-1381 CP Weesp (NL). KRUSE, Cor- A61K 31/00 (2006.01) A61K 31/551 (2006.01) nelis G. [NL/NL]; c/o SOLVAY PHARMACEUTICALS A61K 31/439 (2006.01) A61P 25/18 (2006.01) B.V., IPSI Department, CJ. Van Houtenlaan 36, NL-1381 A61K 31/4439 (2006.01) CP Weesp (NL). (21) International Application Number: (74) Agent: VERHAGE, Marinus; Octrooibureau Zoan B.V., PCT/EP2007/053934 NL-1380 AC Weesp (NL). (22) International Filing Date: 23 April 2007 (23.04.2007) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (25) Filing Language: English CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, (26) Publication Language: English IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, (30) Priority Data: MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 061 13476.3 4 May 2006 (04.05.2006) EP RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, 60/797,355 4 May 2006 (04.05.2006) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (71) Applicant (for all designated States except US): SOLVAY (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS B.V. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
PDF Download
CURRENT THERAPEUTIC RESEARCH VOL. 56, NO. 5, MAY 1995 EFFECTS OF CEREBRAL METABOLIC ENHANCERS ON BRAIN FUNCTION IN RODENTS KOICHIRO TAKAHASHI,l MINORU YAMAMOTO,’ MASANORI SUZUKI,’ YUKIKO OZAWA,’ TAKASHI YAMAGUCHI,l HIROFUMI ANDOH, AND KOUICHI ISHIKAWA2 ‘Department of Pharmacology, Clinical Pharmacology Research Laboratory, Yamunouchi Pharmaceutical Co. Ltd., and ‘Department of Pharmacology, School of Medicine, Nihon University, Tokyo, Japan AFWI’RACT The effects of cerebral metabolic enhancers (indeloxazine, bi- femelane, idebenone, and nicergoline) on reserpine-induced hypother- mia, the immobility period in forced swimming tests, and passive avoidance learning behavior were compared with the effects of ami- triptyline in rodents. Indeloxazine, bifemelane, and amitriptyline antagonized hypothermia in mice given reserpine. Indeloxaxine and amitriptyline decreased the immobility period in mice in the forced swimming test in a dose-dependent manner. The latency of step- through in the passive avoidance test in rats was prolonged by ad- ministration of indeloxazine but shortened by administration of amitriptyline. Neither idebenone nor nicergoline displayed any phar- macologic action in these tests. The results suggest that indeloxaxine possesses an antidepressant activity similar to that of amitriptyline but differs from amitriptyline in its anticholinergic properties and its ability to ameliorate impaired brain function such as that of learning behavior. In addition, indeloxazine exhibited broader effects on brain functions than either bifemelane, idebenone, or nicergoline. INTRODUCTION Cerebral metabolic enhancers (drugs that enhance energy metabolism) including brain glucose and ATP levels such as indeloxazine,1*2 bi- femelane, 3*4idebenone?6 and nicergoline,7>8 are currently used for the treatment of patients with various psychiatric symptoms. These symptoms include reduced spontaneity and emotional disturbance in patients with cerebral vascular disease. -
Nootropic Concepts
Nootropic concepts intelligent ingredient for gut health Nootropics definition Nootropic is a substance that enhances cognition and memory and facilitates learning. Nootropics work in many ways to produce a range of benefits across memory, focus, attention, motivation, relaxation, mood, alertness, stress resistance. Bluenesse® Bluenesse® – an innovative, exclusive lemon balm extract, Melissa officinalis (L.) – supports your mental health. It has an immediate effect on focus, concentration, and memory. Furthermore, it supports a calm and good mood and helps to balance the stress hormone cortisol. Bluenesse® - Nootropics concepts Nootropic benefits of Bluenesse® and the underlying mode of action: Bluenesse® - Nootropics concepts – detailed information: Several, double blind, randomized, placebo-controlled, crossover human study results have shown that Bluenesse® supports nootropic effects on demand. Below, the investigated parameter and mode of action is explained per each nootropic application. Vital Solutions GmbH, Hausingerstrasse 6, D-40764 Langenfeld, +49 (0) 2173 109 82 02 [email protected] www.vitalsolutions.biz . Nootropic concepts Cognitive performance support and enhancing learning & memory: Bluenesse® significantly improves cognitive performance, particularly alertness, working memory and mathematic processing by improving the efficiency of neuronal communication. It activates Muscarinic receptors, which are responsible for the efficient flow of information between neurological cells, so-called “oscillation”, leading to -
Treatment Protocol Copyright © 2018 Kostoff Et Al
Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
First Reversals of Cognitive Decline in Alzheimer's Disease and Its
1/12/2017 First Reversals of Cognitive Decline in Alzheimer’sSystems Therapeutics, Disease and its PresidentPrecursors, Obama, MCI and and the End ofSCI Alzheimer’s Disease Dale E. Bredesen, M.D. Augustus Rose Professor Easton Laboratories for Neurodegenerative Disease Research UCLA Founding President, Buck Institute “There is nothing that will prevent, reverse, or slow the progress of Alzheimer’s disease.” “Everyone knows someone who is a cancer survivor; no one knows an Alzheimer’s survivor.” 1 1/12/2017 30,000,000 patients in 2012 3rd leading cause (James, B. D. et al. Contribution of Alzheimer disease to mortality in the United States. Neurology 82, 1045-1050, doi:10.1212/WNL. 0240 (2014) Pres. Obama and NAPA, 2011 160,000,000 patients in 2050 2 1/12/2017 Women at the epicenter of the epidemic •65% of patients •60% of caregivers •More common than breast cancer 0 Cures 3 1/12/2017 Alzheimer’s Disease (AD) Therapeutic Landscape A production APPROVED A aggregation Donepezil (Aricept) A clearance Rivastigmine (Exelon) Tau aggregation/phosph Galantamine (Razadyne) Cholinergic drugs Tacrine (Cognex) Others Memantine (Namenda) PHASE 3 PHASE 2 PHASE 1 Solanezumab ELND005 PBT2 AL-108 GSK933776 NIC5-15 PF04360365 AF102B MABT5102A Bapineuzmab Valproate Bryostatin-1 Nicotinamide Talsaclidine EHT-0202 NP12 ACC001 UB311 Alzemed Antioxidant BMS708163 Lithium AN1792 R1450 Begacestat Semagacestat Statins ABT089 NGF CAD106 V950 PF3084014 AZD3480 SB742457 Flurizan Dimebon E2012 Huperzine-A PRX03140 CTS21166 Rosiglitazone EGCg EVP6124 PUFA MK0752 MEM3454 TTP448 Phenserine CHF5074 PF-04447943 Clinical Trial in AD terminated “Game of Throwns” (243/244) R.I.P. R.I.P. R.I.P. -
Sibelium 5 Mg Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Sibelium 5 mg Tablets flunarizine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. In this leaflet: 1. What Sibelium is and what it is used for 2. What you need to know before you take Sibelium 3. How to take Sibelium 4. Possible side effects 5. How to store Sibelium 6. Contents of the pack and other information 1. WHAT SIBELIUM IS AND WHAT IT IS USED FOR What is Sibelium? Sibelium tablets contain flunarizine. They belong to a group of medicines known as calcium channel blockers, which work by preventing the narrowing of blood vessels. What is it used for? Sibelium Tablets are for use in adults. They have been prescribed for you to help your migraine-type headaches. If you take Sibelium Tablets regularly they can help you get fewer headaches, or less painful headaches. They can stop some migraine attacks starting and help make other attacks less severe. While you are taking Sibelium Tablets, your doctor will review your treatment at regular intervals in order to assess your response to the medicine. -
Mode of Action
STROKE TBI DEMENTIA Mode of Action Reconnecting Neurons. Empowering for Life. NEW MULTI-MODAL THERAPIES FOR NEUROLOGICAL DISORDERS Sonic hedgehog (Shh) The Sonic Hedgehog (Shh) signalling pathway regulates the development Smoothened of organs including the organization of the brain. For example, the Shh (Smo) Patched (Ptch) activates the Gli complex, which is responsible for the expression of develop- mental genes underpinning neurorecovery and leading to an amplification of natural recovery. Gli Complex Gli Repressor Gli Activator Cerebrolysin activates the Shh pathway1 Cerebrolysin has a promoting effect on neurogenesis and oligodendrogenesis via stimulating the expression of the Shh signalling pathway. Cerebrolysin increases mRNA modulation of Shh and its receptors ‘Patched’ (Ptch) and ‘Smoothened’ (Smo). Shh PTCH Smo 5 * * 3 * 3 4 (n=9) (n=9) *p<0.05 (n=9) *p<0.05 *p<0.05 3 2 2 2 1 1 Fold changes (mean±SE) changes Fold (mean±SE) changes Fold 1 (mean±SE) changes Fold 0 0 0 0 20 0 20 0 20 CERE (µl/ml) CERE (µl/ml) CERE (µl/ml) Figure 1: Cerebrolysin stimulates the expression of the sonic hedgehog signalling pathway components in neural progenitor cells. Graphs show mRNA levels in an in vitro experiment. Studies confirm the important role of the sonic hedgehog pathway in post-stroke brain repair and functional recovery, and suggests the Shh pathway to be a possible target for prolongation of the therapeutic window after stroke.2 MAINTENANCE AND RECOVERY OF THE NEURONAL NETWORK Neurotrophic factors (NTFs) are signaling molecules that maintain, protect, and restore the neuronal network and ensure proper functioning of the brain.